NCT01232296 - A Study of Dovitinib Versus Sorafenib in Adult Patients With Hepatocellular Carcinoma (HCC) as a First Line Treatment | Biotech Hunter

Enrollment

162

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions

Hepatocellular Carcinoma

Interventions

DRUG

dovitinib

500 mg p.o. o.d. 5 days on/2 days off

DRUG

sorafenib

400 mg p.o. b.i.d.

Trial Locations (24)

112

Novartis Investigative Site, Taipei

10048

Novartis Investigative Site, Taipei

10330

Novartis Investigative Site, Bangkok

10700

Novartis Investigative Site, Bangkok

33305

Novartis Investigative Site, Kuei-Shan Chiang

40002

Novartis Investigative Site, Khon Kaen

40705

Novartis Investigative Site, Taichung

50200

Novartis Investigative Site, Chiang Mai

90110

Novartis Investigative Site, Songkhla

100039

Novartis Investigative Site, Beijing

210002

Novartis Investigative Site, Nanjing

308433

Novartis Investigative Site, Singapore

310016

Novartis Investigative Site, Hangzhou

710032

Novartis Investigative Site, Xi’an

Unknown

Novartis Investigative Site, Shatin, New Territories

Novartis Investigative Site, Hong Kong

277-8577

Novartis Investigative Site, Kashiwa

232-0024

Novartis Investigative Site, Yokohama